Press Releases

SAN DIEGO, Oct. 29, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP, is investigating potential claims against Geron Corporation ("Geron") (NASDAQ: GERN) on behalf of investors.  Geron is a biopharmaceutical company. Specifically, the investigation seeks to determine whether certain statements regarding the results of a clinical drug stud

CAMBRIDGE, Mass., Oct. 29, 2019 /PRNewswire/ -- Disc Medicine, a hematology company applying new insights in hepcidin biology to develop therapies that restore red blood cell production in hematologic diseases, today announced the completion of a $50 million Series A financing. The company's novel approach focuses on targeting hepcidin,

CAMBRIDGE, Mass., Oct. 29, 2019 /PRNewswire/ -- Disc Medicine, a hematology company that is applying new insights in hepcidin biology to develop therapies addressing ineffective red blood cell production in hematologic diseases, today announced that it has entered into an exclusive license agreement with AbbVie for the worldwide rights to a series of hemojuvelin antagoni

ROCKVILLE, Md., Oct. 29, 2019 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Tuesday, November 5, 20

OLDWICK, N.J., Oct. 29, 2019 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a clinical stage biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third quarter 2019 financial results on Tuesday, November 5, 2019.

SOUTH SAN FRANCISCO, Calif., Oct. 29, 2019 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology therapeutics, today announced initial safety data in ovarian cancer patients from its ongoin

CARMIEL, Israel, Oct. 29, 2019 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that it

ALBUQUERQUE, N.M., Oct. 29, 2019 /PRNewswire/ -- In a move that will further strengthen its leadership position in helping health systems and life sciences companies deliver personalized care guidance through the emerging category of care process automation,

SEATTLE, Oct. 29, 2019 /PRNewswire/ -- In a move that will further strengthen its leadership position in helping health systems and life sciences companies deliver personalized care guidance through the emerging category of care process automation,

TEL AVIV, Israel, Oct. 29, 2019 /PRNewswire/ --  BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology, announced today that it will deliver a proffered paper (oral) presentation at the